Clinical trial
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With…
NCT03201445 · Galapagos NV, Industry · Terminated
Key facts
| NCT number | NCT03201445 |
|---|---|
| Title | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease |
| Official title | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease |
| Acronym | MANTA |
| Lead sponsor | Galapagos NV, Industry |
| Collaborators | Gilead Sciences Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Inflammatory Bowel Disease |
| Intervention type | Drug |
| Interventions | Filgotinib, Placebo, Standard of Care |
| Enrollment | 139 |
| Start date | Jul 11, 2017 |
| Primary completion | Nov 20, 2020 |
| Completion | Oct 24, 2023 |
| First posted | Jun 28, 2017 |
| Last update posted | Oct 9, 2024 |
| Countries | Australia, Austria, Germany, India, New Zealand, Poland, Romania, Russia, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: